What question did this study set out to answer?

To evaluate the prognostic impact of IDH1 and IDH2 mutations on survival outcomes in patients with surgically resected and unresectable intrahepatic cholangiocarcinoma.

August 1, 2026JCO Precision Oncology

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma

View Full Paper

Ask AI

Bookmark

To evaluate the prognostic impact of IDH1 and IDH2 mutations on survival outcomes in patients with surgically resected and unresectable intrahepatic cholangiocarcinoma.
Retrospective analysis of N=795 adults with intrahepatic cholangiocarcinoma treated with curative-intent resection or managed nonoperatively across two centers (MSKCC and Erasmus).
Next-generation sequencing was conducted to determine IDH1/2 mutation status and concurrent high-risk alterations (TP53, KRAS, CDKN2A).
Survival outcomes were evaluated using Kaplan-Meier survival curves and multivariable Cox proportional hazards regression models.
IDH mutations were identified in 25% of patients, and overall survival across the full cohort was 32 months for IDH-mutant versus 28 months for IDH wild-type (P = .2); high-risk co-alterations were significantly more common in wild-type tumors (OR, 2.26; q < 0.001).
In resected patients (43%), IDH mutation was initially associated with improved recurrence-free survival (20 vs 14 months; P = .018), but this benefit disappeared after adjusting for high-risk alterations (HR, 0.78; P = .095; overall survival HR, 0.88; P = .4).
In unresectable disease, progression-free survival (9.4 vs 9.1 months; P = .7) and overall survival (22 vs 18 months; P = .13) showed no significant differences by IDH status, confirming IDH was not an independent survival predictor.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study reveals IDH mutations do not independently predict survival in intrahepatic cholangiocarcinoma, indicating IDH status alone should not guide prognosis.

Cite This Study

Harvey et al. (2026) studied this question.

synapsesocial.com/papers/6a73ea0dbbad068246a8c2b0 https://doi.org/10.1200/po-25-01261

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals IDH mutations do not independently predict survival in intrahepatic cholangiocarcinoma, indicating IDH status alone should not guide prognosis.

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma

Key Points

Discussion

Implication

Cite This Study

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading